[The intraocular pressure lowering effects of UF-021, a novel prostaglandin related compound, in animals].
The ophthalmic solution of UF-021, a novel prostaglandin (PG) related compound, was investigated for its intraocular pressure (IOP) reducing activity and local ocular side effects in different species of animals. UF-021 ophthalmic solution (0.03 to 0.24%), when topically applied to the eyes of rabbits, caused dose-dependent IOP reduction (2.8 to 5.2 mmHg), without transient IOP rise. Both in cats and monkeys, UF-021 ophthalmic solution (0.12%) elicited rapid, significant IOP reduction (ca. 9 mmHg and 2 mmHg, respectively), without any controversial, local ocular side effects being revealed. On the other hand, PGE2, PGF2 alpha-isopropyl ester all brought about marked increases in IOP prior to development of their IOP reducing activities. In addition, these primary PGs showed intense local ocular irritation, which presented a striking contrast with UF-021. Enhancement of IOP reducing activity, coupled with freedom from any significant ocular side effects, as described above, suggests that UF-021 ophthalmic solution could be promising as a new anti-glaucoma agent.
Ueno
R
R
Ueno Institute for Medical Science, Ueno Fine Chemicals Industry Limited, Sanda, Japan.
Yoshida
S
S
Deguchi
T
T
Kato
I
I
Oda
T
T
Hayashi
Y
Y
Kuno
S
S
D000818:Animals; D002415:Cats; D015237:Dinoprost / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D007429:Intraocular Pressure / Q000187:drug effects*; D008251:Macaca; D008297:Male; D011817:Rabbits
C041158:prostaglandin F2 isopropyl ester; C072630:isopropyl unoprostone; D015237:Dinoprost; D015232:Dinoprostone